Understand the source comparison
VIP Anti-Inflammatory: Dosing, Stability, and Formulation Comparison
The following table compares VIP formulation variables that determine experimental reproducibility and research outcomes. Formulation type, storage conditions, and delivery route directly impact VPAC receptor engagement and inflammatory pathway suppression. Ly
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The following table compares VIP formulation variables that determine experimental reproducibility and research outcomes. Formulation type, storage conditions, and delivery route directly impact VPAC receptor engagement and inflammatory pathway suppression.
- Lyophilized VIP (native sequence)
- −20°C stable 24+ months; reconstituted 2–8°C stable 7–14 days
- 10–50 mcg/kg in rodents; 100–300 mcg in human trials
- SC, IN, IV, nebulized
- Full VPAC1/VPAC2 affinity; no selectivity bias; matches endogenous peptide structure
- Gold standard for mechanistic studies where native receptor pharmacology must be preserved; requires frequent dosing due to short half-life
- PEGylated VIP (5 kDa N-terminal)
- 2–8°C stable 6–12 months reconstituted
- 25–100 mcg/kg (lower frequency due to extended half-life)
- SC, IV
- Extended half-life (4–6 hours); reduced dosing frequency
- Suitable for chronic studies where repeated dosing is impractical; VPAC1 affinity reduced 40–60%; less predictable immune modulation
- VIP + DPP-IV inhibitor co-formulation
- −20°C stable 18+ months; reconstituted 2–8°C stable 10–14 days
- VIP 10–50 mcg/kg + sitagliptin 10 mg/kg
- Extends native VIP half-life 3–5-fold without altering receptor affinity
- Optimal for systemic immune studies requiring native VPAC pharmacology with practical dosing intervals; adds co-administration complexity
- Intranasal VIP (buffered saline)
- 2–8°C stable 30 days reconstituted
- 5–20 mcg per nostril (human); 1–5 mcg (rodent)
- IN
- Direct CNS delivery; bypasses systemic degradation; peak brain levels in 20–30 min
- Best route for neuroinflammatory models; variable absorption based on nasal mucosa integrity; not suitable for systemic immune studies
- Nebulized VIP (isotonic formulation)
- 2–8°C stable 14–21 days; must be particulate-free
- 100–300 mcg per nebulization session
- Inhaled
- Highest local lung concentrations; minimal systemic exposure
- Superior for pulmonary inflammation research; requires nebulization equipment; not applicable to CNS or GI research
- Dosing in VIP anti-inflammatory research must account for species differences in VPAC receptor density and peptide metabolism. Mice and rats demonstrate 50–70% higher hepatic and renal peptidase activity compared to humans, requiring 2–3-fold higher per-kilogram doses to achieve equivalent tissue exposure. Standard murine dosing ranges from 10–50 mcg/kg subcutaneously for immune modulation studies, while CNS protection models often use intranasal doses of 1–5 mcg to achieve therapeutic hypothalamic and cortical concentrations. Human trials have evaluated doses from 25 mcg (single intranasal) to 300 mcg (nebulized) with acceptable safety profiles. Vasodilation and transient hypotension represent the primary dose-limiting effects above 500 mcg systemically.
- Reconstitution technique significantly impacts VIP stability and activity. VIP is synthesized as a lyophilized powder and must be reconstituted in sterile water or bacteriostatic water at neutral pH (7.0–7.4). Acidic or alkaline reconstitution buffers accelerate peptide bond hydrolysis. VIP stored at pH 5.5 loses 40% activity within 72 hours at 4°C, while pH 7.2 formulations retain >95% activity for 14 days under identical conditions. Researchers should reconstitute VIP immediately before use when possible, and avoid freeze-thaw cycles that denature tertiary structure and reduce receptor binding affinity by 30–50% per cycle.
- Storage temperature adherence is non-negotiable. Unreconstituted VIP stored at −20°C maintains full activity for 24+ months, but even brief excursions to room temperature initiate degradation. A single 4-hour exposure to 25°C reduces potency by approximately 8–12%. Once reconstituted, VIP must remain at 2–8°C and should be aliquoted into single-use volumes to prevent repeated warming during withdrawal. Our experience working with research institutions has shown that storage protocol violations are the most common source of experimental variability. Investigators reporting inconsistent VIP effects frequently trace failures to temperature excursions during shipping or storage rather than protocol design flaws. Real Peptides' VIP is shipped with cold chain integrity monitoring and includes storage verification protocols to ensure peptide stability from synthesis through experimental application.